Blood level of CD45+ platelets and development of restenosis after drug-eluting stent implantation in patients with stable coronary artery disease

Gabbasov, Zufar; Kozlov, Sergey; Byazrova, Svetlana; Saburova, O.; Melnikov, Ivan; Čaprnda, Martin; Curilla, Eduard; Gašpar, Ľudovít; Kružliak, Peter; Smirnov, Vladimir

doi:10.1007/s00508-016-1074-x

Cited by 3 publications

(6 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…20 In our recent work, we showed that increased counts of platelets with CD45 leukocyte antigens are characteristic for patients with restenosis in DES. 14 In the present article, we demonstrate that patients with type 2 DM and in-stent restenosis in DES have higher counts of CD45+ platelet in circulation than patients with in-stent restenosis in DES but without type 2 DM (OR: 4.51 vs 2.31, respectively). Considering the opinion that chronic inflammation underlies restenosis development after DES, the increased CD45+ platelet count may reflect a higher level of platelet–leukocyte interactions.…”

Section: Discussionsupporting

confidence: 47%

“…23 –25 In our recent work, we have already reported elevated NLR in persons with restenosis in DES. 14 This was found in the general population. In the present work, we demonstrate that in patients with type 2 DM and in-stent restenosis in DES, NLR is elevated even more than in the general population with restenosis (OR: 3.09 vs 2.68, respectively).…”

Section: Discussionmentioning

confidence: 83%

“…13 In our recent work, we revealed that CD45+ platelet count and neutrophil to lymphocyte ratio (NLR) predict the development of restenosis in DES. 14 In the present work, we further investigated the predictive ability of these biomarkers in patients with coronary artery disease (CAD) and type 2 diabetes mellitus (DM).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Novel Biomarkers for Coronary Restenosis Occurrence After Drug-Eluting Stent Implantation in Patients With Diabetes Having Stable Coronary Artery Disease

Gabbasov

Kozlov

Melnikov

et al. 2018

Clin Appl Thromb Hemost

Self Cite

View full text Add to dashboard Cite

The purpose of the study was to assess whether the occurrence of restenosis is associated with CD45þ platelet count and neutrophil to lymphocyte ratio in patients with type 2 diabetes mellitus (DM) after drug-eluting stent (DES) implantation for stable coronary artery disease (CAD). The study comprised 126 patients, including 55 patients with type 2 DM and stable CAD who underwent elective coronary artery stenting with DES and follow-up angiography within 6 to 12 months. Blood samples were collected from each patient on the morning of the coronary angiography procedure. The variables related to in-stent restenosis were selected by logistic regression analysis. The logistic regression analysis showed that 2 inflammatory factors, CD45þ platelet count (odds ratio [OR] ¼ 4.51, 95% confidence interval [CI]: 1.50-13.50, P ¼ .007) and neutrophil to lymphocyte ratio (OR ¼ 3.09, 95% CI: 1.05-9.10, P ¼ .04), were significantly associated with the risk of in-stent restenosis after stenting with DES in patients with stable CAD and type 2 DM. A receiver operator characteristic curve analysis indicated that the area under the curve was 0.83% (0.05%; P < .001), which showed that the logistic model had good predictive accuracy (based on CD45þ platelet count and neutrophil to lymphocyte ratio) for the risk of in-stent restenosis development in DES in patients with CAD and type 2 DM. Two novel biomarkers of restenosis, CD45þ platelet count and neutrophil to lymphocyte ratio, may be effectively used to predict in-stent restenosis after DES implantation in patients with CAD and type 2 DM.

show abstract

Section: Discussionsupporting

confidence: 47%

Section: Discussionmentioning

confidence: 83%

See 1 more Smart Citation

Novel Biomarkers for Coronary Restenosis Occurrence After Drug-Eluting Stent Implantation in Patients With Diabetes Having Stable Coronary Artery Disease

Gabbasov

Kozlov

Melnikov

et al. 2018

Clin Appl Thromb Hemost

Self Cite

View full text Add to dashboard Cite

show abstract

“…[66][67][68] Sreeramkumar et al 69 showed that activated platelets can bind to neutrophils causing inflammation of the blood vessel wall and promoting atherosclerosis. Gabbasov et al 40 found that plasma CD45 þ platelets are closely related to restenosis after DES implantation in patients with CAD. However, the mechanism of platelet-WBC interaction is still unknown.…”

Section: Parameters Of Platelet Activationmentioning

confidence: 99%

Blood Cell Parameters and Predicting Coronary In-Stent Restenosis

2019

View full text Add to dashboard Cite

Major advances in coronary interventional techniques and pharmacotherapy as well as the use of drug-eluting stents (DESs) have considerably reduced the risk of in-stent restenosis (ISR). However, ISR remains a major clinical challenge. Inflammation and platelet activation are important processes that underlie the pathophysiology of ISR. Parameters related to blood cells, entailing both cell count and morphology, are useful markers of the inflammatory response and platelet activation in clinical practice. Recent studies have highlighted several new combined or derived parameters related to blood cells that independently predict ISR after DES implantation. The neutrophil/lymphocyte ratio, an inflammatory marker, is regarded as a predictor of the risk of ISR and the stability of atherosclerotic plaques. The mean platelet volume, a widely used platelet activation parameter, has been shown to be a predictor of the risk of ISR and the efficacy of antiplatelet therapy. Other markers considered include the platelet/lymphocyte ratio, red blood cell distribution width, and platelet distribution width. This review provides an overview of these parameters that may help stratify the risk of coronary angiographic and clinical outcomes related to ISR.

show abstract

“…Expression of CD45, a common leukocyte antigen, was observed on megakaryocytes and only on 0.34 % of mature platelets in healthy individuals [35,36]. In this study, we have described for the first time EVs with CD61+ and CD45+ co-expression.…”

Section: Discussionmentioning

confidence: 85%

Extracellular Vesicles in the Blood of Dogs with Cancer—A Preliminary Study

Żmigrodzka

Rzepecka

Cywińska

et al. 2019

Animals

View full text Add to dashboard Cite

Extracellular vesicles (EVs) are a heterogeneous population of submicron-sized structures released during the activation, proliferation, or apoptosis of various types of cells. Due to their size, their role in cell-to-cell communication in cancer is currently being discussed. In blood, the most abundant population of EVs is platelet-derived EVs (PEVs). The aim of this study was to estimate the absolute number and the origin of EVs in the blood of healthy dogs and of dogs with various types of cancer. The EV absolute number and cellular origin were examined by flow cytometry technique. EVs were classified on the basis of surface annexin V expression (phosphatidylserine PS+) and co-expression of specific cellular markers (CD61, CD45, CD3, CD21). The number of PEVs was significantly higher in dogs with cancer (median: 409/µL, range: 42–2748/µL vs. median: 170/µL, range: 101–449/µL in controls). The numbers of EVs derived from leukocytes (control median: 86/µL, range: 40–240/µL; cancer median: 443/µL, range: 44–3 352/µL) and T cells (control median: 5/µL, range: 2–66/µL; cancer median: 108/µL, range: 3–1735/µL) were higher in dogs with neoplasia compared to healthy controls. The estimation of PEV and leukocyte-derived EV counts may provide a useful biological marker in dogs with cancer.

show abstract

Blood level of CD45+ platelets and development of restenosis after drug-eluting stent implantation in patients with stable coronary artery disease

Abstract: The acquired data indicate the presence of a close relationship between circulating CD45+ platelets and restenosis development after DES implantation in patients with stable CAD.

Cited by 3 publications

References 28 publications

Novel Biomarkers for Coronary Restenosis Occurrence After Drug-Eluting Stent Implantation in Patients With Diabetes Having Stable Coronary Artery Disease

Novel Biomarkers for Coronary Restenosis Occurrence After Drug-Eluting Stent Implantation in Patients With Diabetes Having Stable Coronary Artery Disease

Blood Cell Parameters and Predicting Coronary In-Stent Restenosis

Extracellular Vesicles in the Blood of Dogs with Cancer—A Preliminary Study

Contact Info

Product

Resources

About